Chapter 7

Vascular phenotype and subclinical inflammation in diabetic Asian Indians without overt cardiovascular disease

A Ray ¹, ED Beishuizen ¹, A. Misra ², MV Huisman ¹, JT Tamsma ¹

¹ Department of General Internal Medicine and Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
² Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

Diabetes Research and Clinical Practice 2007; 76:390-396
ABSTRACT

Objective
Although Asian Indian (AI) patients with diabetes mellitus type 2 (DM2) are at high-risk for cardiovascular disease (CVD), not all patients develop CVD. The vascular phenotype of AI-DM2 without CVD has not been elucidated and may point to protective features.

Research Design and Methods
Using baseline data from a clinical trial we provide an initial description of vascular parameters in AI-DM2 compared to Europid Caucasian controls (ECs) matched for age and gender. Endpoints of the study were endothelial function, low-grade systemic inflammation (CRP) and carotid intima-media thickness (CIMT).

Results
AIs had longer duration of diabetes, worse glycemic control and more microangiopathy. Both groups demonstrated marked endothelial dysfunction. CRP levels were similar: 1.7 (4.9) mg/L in AIs and 2.8 (3.6) mg/L in ECs. CIMT values were significantly lower in AI-DM2 than EC-DM2 (0.655 mm (0.12) versus 0.711 mm (0.15), p = 0.03). Multiple regression analysis showed that variability in CRP was mainly determined by waist circumference, not by ethnicity. In contrast, ethnicity was a significantly explanatory variable for CIMT.

Conclusions
Vascular phenotype of AI-DM2 without CVD was characterized by endothelial dysfunction and relatively low levels of CRP, comparable to EC-DM2 controls. In contrast, lower CIMT values were observed in AI-DM2 despite longer duration of diabetes and worse metabolic control. We propose that mechanisms slowing its progression may have atheroprotective potential in AI-DM2.
INTRODUCTION

In the Netherlands a large community from the former Dutch colony of Surinam, originally of Asian Indian (AI) descent, has settled. Epidemiologic data suggest that the excess of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD) noted in AI populations across the world\(^1\)\(^2\) is also present in AIs in the Netherlands\(^3\)^\(^4\). An important pathogenic factor is the high prevalence of insulin resistance and DM2 in AIs. However, traditional risk factors do not fully explain the excess of CVD\(^5\). Several other risk factors such as low-grade systemic inflammation\(^6\)^\(^7\) and endothelial dysfunction\(^8\)^\(^9\) have been proposed to contribute to initiation and progression of atherosclerosis in AIs.

Despite the well-established high cardiovascular risk, not all AI-DM2 develop CVD. The vascular phenotype of AI-DM2 without CVD has not been elucidated and may point to protective features regarding the development of CVD. We aimed to provide a first evaluation of vascular parameters in AIs and matched EC controls with DM2 but without CVD.

RESEARCH DESIGN AND METHODS

Subjects

This study is a substudy of a previously reported randomized clinical trial. The study design and results of which have been described elsewhere\(^10\)^\(^11\)^\(^12\). Using this database, we were able to identify 48 subjects of AI descent and 48 EC subjects from the same cohort matched for age and gender. There were no differences in demographics between the two groups, both living in an urban area in the Netherlands. The predecessors of the AI population migrated from India to Surinam starting 1873. Most of our study subjects were first generation immigrants in this country and third or fourth generation out of India. Patients were eligible for the study if they had been diagnosed with DM2 for at least 1 year, aged 30–80 years and without CVD. CVD was defined as angina pectoris, clinically manifest coronary artery disease, ECG criteria for a past myocardial infarction, ischemic stroke, peripheral artery bypass surgery, percutaneous transluminal angioplasty or amputation because of atherosclerotic disease. Patients with marked dyslipidemia (fasting total cholesterol >6.9 mmol/L or triglycerides >6.0 mmol/L) were excluded from the original population, as prior statin therapy was an exclusion criterion in the clinical trial. Eligible patients gave their written informed consent. The study was approved by the hospital's Medical Ethics Committee.

Endpoints

The endpoints of this study were differences in inflammatory markers (serum C-reactive protein (CRP) and fibrinogen levels), endothelial function (as estimated using measurement of flow mediated dilation (FMD)) and carotid intima-media thickness (CIMT) as a
non-invasive measure of atherosclerosis. Furthermore, presence and risk of coronary ath-
erosclerosis was assessed using measurement of silent myocardial ischemia (Ambulatory
Electrocardiogram(AECG)) and UKPDS risk scores for CVD.

**Clinical examination**

Anthropometric measurements were performed by two observers using standardized meth-
ods. Waist circumference was measured midway between the iliac crest and the lowest costal
margin at the end of normal expiration; hip circumference was measured at the maximal
circumference at the level of the femoral trochanter. Blood pressure was measured using a
standard sphygmomanometer after a 10 min resting period in supine position. Hypertension
was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90
mmHg. The presence or absence of retinopathy was determined from the subject’s medical
files, wherein reports from ophthalmologists were retrieved.

**Laboratory investigations**

Lipid and safety measurements were performed at the Department of Clinical Chemistry and
Hematology of the Leyenburg Hospital, according to ISO 15189 standard procedures. Blood
samples were collected after an overnight fast. A urine sample was collected for the determi-
nation of the albumin over creatinine ratio. Serum or plasma was isolated by centrifugation at
2900 rpm for 5 min. Levels of total cholesterol and triglycerides were measured by enzymatic
methods on a Synchron LX20-analyzer (Beckman Coulter, Brea, USA). LDL cholesterol was
calculated according to the Friedewald formula. If triglycerides were > 4.5 mmol/L, LDL
cholesterol was measured directly with the use of a reagent kit (Genzyme Diagnostics).
HDL cholesterol levels were determined after dextran sulfate-magnesium precipitation of
apolipoprotein B-containing lipoproteins. Creatinine kinase and alaninaminotransferase
were measured by an enzymatic rate method on a Synchron LX20 multichannel chemistry
analyzer, according to IFCC methods. HbA1c was measured by HPLC on a Variant II (BioRad,
USA). For the urine sample, a Jaffé’ rate method was used for the measurement of creatinine
on a Synchron LX20- analyzer, while albumin was measured by rate nephelometry. Presence
of microalbuminuria was defined as >2.5 g albumin/ mol creatinine for men and >3.5 g albu-
min/mol creatinine for women.

The high-sensitivity CRP assay was performed in the Leiden University Medical Center with
the Tinaquant CRP (latex) high-sensitive assay from Roche. This particle enhanced immuno-
turbidimetric assay was carried out on a Roche Module P using serum.

**CVD risk scores, AECGs and metabolic syndrome criteria**

Absolute 10-year risk scores for developing a cardiovascular event were calculated using the
UKPDS risk engine Version 2.0. For patients using anti-hypertensive medication the systolic
blood pressure was arbitrarily set at 160 mmHg. The AECG registration and analysis were
conducted as previously described \textsuperscript{11}. Criteria for the presence of the metabolic syndrome (MS) were according to the European Group for the Study of Insulin Resistance modification of the WHO guidelines \textsuperscript{15,16}: presence of DM2 (per definition in our population), and two or more of the following characteristics: waist circumference \( \geq 94 \) cm in males and \( \geq 80 \) cm in females; triglycerides \( >1.7 \) mmol/L; HDL cholesterol \( <0.9 \) mmol/L in males and \( <1.0 \) mmol/L in females; blood pressure \( \geq 140/\geq 90 \) mmHg.

\textbf{Ultrasound protocol}

Ultrasound imaging was performed with an Acuson Aspen scanner with a linear array 7.5 MHz probe. For FMD, an optimal longitudinal image of the brachial artery at, or just above the elbow, was established and kept stable using a specially designed fixative. The exact FMD protocol was described earlier \textsuperscript{12}. For CIMT, all images were recorded digitally for off-line, blinded, analysis by an independent core laboratory, Heartcore, Leiden, the Netherlands as described previously \textsuperscript{10}. Briefly, the left and right distal 1.0 cm of the common carotid arteries, near and far walls, were examined longitudinally in the angle resulting in an optimal and maximal CIMT (while avoiding plaques). For each segment, three R-wave triggered images were stored. Mean CIMT was measured, when possible, over the entire 1 cm of the vessel segment. Mean common CIMT was obtained by averaging the mean IMTs of far and near wall, left and right.

\textbf{Statistical analysis}

All binary data were analyzed using the Pearson Chisquare test. All continuous outcome data were significantly skewed and therefore analyzed using the non-parametric Mann–Whitney test or log transformed (hsCRP, Lp(a)) before being analyzed using the Student’s t-test. Values are reported as medians (IQR). p-Values \(<0.05\) were considered statistically significant. Correlations were calculated with the Spearman’s rank test. To test the impact of correlated parameters on the variability of the outcome variables a stepwise regression analysis was performed.

\textbf{RESULTS}

Patient characteristics are given in Table 1. Despite similar age distribution AIs had a significantly longer duration of diabetes (12.4 years versus 6.3 years; \( p < 0.001 \)) and worse glycemic control as shown by higher median HbA1c levels (7.85% versus 7.20%; \( p = 0.006 \)). Microangiopathy was observed more frequently in AIs, as shown by elevated prevalence of retinopathy (29% versus 6%; \( p = 0.003 \)) and higher level of microalbuminuria (1.3 mg/L versus 0.6 mg/L; \( p = 0.009 \)).
Cardiovascular risk and anthropometry

Smoking was less prevalent in AIs compared to ECs, both at present and ex-smokers. No significant differences were observed in hypertension (defined as systolic blood pressure \( \geq 140 \) mmHg and /or diastolic blood pressure \( \geq 90 \) mmHg or the use of anti-hypertensive medication) and family history of CVD in first degree relatives. Lipid parameters including plasma HDL cholesterol levels were comparable in both ethnic groups. Lp(a) was significantly different between the groups (215.5 mg/dL (410) in AIs versus 95.0 mg/dL (316) in ECs (\( p = 0.02 \)). The UKPDS risk scores for myocardial infarction were found to be 14.9%/10 years in AIs versus 10.5%/10 years in ECs (\( p = \text{NS} \)).

The anthropometric data were summarized in Table 2. AIs were significantly smaller and lighter. EC women had higher values for waist and hip circumference, as well as higher average BMI as compared to AI women. In men no differences were observed regarding these parameters. The MS score was fully comparable in the two groups, and did not change using ethnicity-specific cut-off values as recently proposed by the International Diabetes Federation (data not shown).

<table>
<thead>
<tr>
<th>Table 1 Patient characteristics and laboratory findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian Indians (n=48)</td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>Male gender</td>
</tr>
<tr>
<td>Age (years)*</td>
</tr>
<tr>
<td>Diabetes duration (years)*</td>
</tr>
<tr>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Retinopathy</td>
</tr>
<tr>
<td>Microalbuminuria</td>
</tr>
<tr>
<td>Microalbuminuria† (mg/L)</td>
</tr>
<tr>
<td>Family history of CVD</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Smokers</td>
</tr>
<tr>
<td>UKPDS (%/10 years)</td>
</tr>
<tr>
<td>Creatinine (mcmol/L)</td>
</tr>
<tr>
<td>Clearance (mL/min)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
</tr>
<tr>
<td>Lipoprotein(a) † (mg/dL)</td>
</tr>
<tr>
<td>Fibrinogen (g/L)</td>
</tr>
<tr>
<td>CRP† (mg/L)</td>
</tr>
<tr>
<td>CRP ≥ 3.0 mg/L</td>
</tr>
</tbody>
</table>

All continuous data are expressed in medians (IQR) and compared using non-parametric test (Mann–Whitney) except * and †.

* Data were normally distributed and expressed in means (S.D.), compared using Student’s t-test.
† Data were compared after log transformation using Student’s t-test.
Inflammation, endothelial function and vascular parameters

No differences were observed between the groups for low-grade chronic inflammation as assessed by CRP. The median value was 1.7 mg/L (4.9) in AIs versus 2.8 mg/L (3.6) in ECs (p = 0.83). In addition the number of subjects with evidence of low-grade inflammation (defined as CRP levels ≥ 3 mg/L and <15 mg/L) did not significantly differ between the groups and was 14 (29%) in AIs and 18 (38%) in ECs (p = 0.39). Median serum levels of fibrinogen were comparable (3.6 g/L (1.9) in AIs and 3.2 g/L (1.3) in ECs; p = 0.88).

Endothelial dysfunction was observed in both groups with FMD levels under 2% (Table 2) but comparable between AIs and ECs. In both groups nine subjects (19.1%) had abnormal findings on their AECG suggesting silent ischemia. These 18 subjects had comparable values of IMT (0.730 mm (0.18) versus 0.680 mm (0.15) in subjects with normal AECGs, p = 0.472). Further analysis of these subjects revealed no ethnic difference for the number of ischemic episodes, the duration of ischemia or the ischemic burden (data not shown).

AIs were found to have significantly lower median CIMT values of 0.655 mm (0.12) compared to ECs (0.711 mm (0.15); p = 0.03). Luminal diameter was not a predetermined endpoint, but
was assessed in 66 cases (35 ECs and 31 AIs). In this subset AIs had smaller lumina (7.294 mm (1.12) versus 7.770 mm (1.05) in ECs; p = 0.02).

In a stepwise regression analysis log CRP, IMT, FMD and log Lp(a) were entered as dependent variables (Table 3). Log Lp(a) was included because it has consistently been found to be high in AI patients. Covariables that were taken into account were: age, race, duration of diabetes, HbA1c, smoking status, waist circumference, LDL- and HDL cholesterol, triglycerides and systolic blood pressure. FMD was impacted by age only. The strongest determinant of variance in Lp(a) levels was race. Waist circumference had the greatest impact on variance in CRP levels and race did not contribute significantly. Finally, age and race explained variance in CIMT.

<table>
<thead>
<tr>
<th>Table 3 Multiregression analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>CIMT (r²=0.13)</td>
</tr>
<tr>
<td>FMD (r²=0.05)</td>
</tr>
<tr>
<td>Log CRP (r²=0.16)</td>
</tr>
<tr>
<td>Log Lp(a) (r²=0.11)</td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

In this study we observed, for the first time, a low CIMT in AI-DM2 patients without CVD, compared to matched EC counterparts. Low CIMT was present despite longer duration of diabetes and worse glycemic control, the significance of the latter being illustrated by increased measures of microangiopathy in AI-DM2. Longer duration of diabetes and increased prevalence of microalbuminuria are in line with previous publications on AIs in the Netherlands, and elsewhere 17,18. In addition, the high Lp(a) levels observed in AIs have been previously reported 18. Thus, the low CIMT is a new and intriguing finding and it was found in a population with very similar characteristics to these earlier reports with one exception: absence of overt CVD, despite presence of DM2 in our study population.

Previous studies have suggested that endothelial function may be more vulnerable in AIs than in ECs and thus contributes to the development of atherosclerosis 19. In our population of DM2 patients without CVD both ethnic groups exhibited endothelial dysfunction and we could not demonstrate ethnic differences.

CRP is a cardiovascular risk indicator with additional predictive power to the Framingham risk scores 20. CRP levels were found to be higher in AI migrants compared to native populations in several 7,21 but not all 22 studies. We observed intermediate values of CRP in AI-DM2 and EC-DM2 with medians of, respectively, 1.7 and 2.8 mg/L. It could be hypothesized that an attenuated individual inflammatory response could be part of a protective phenotype, thus being in line with epidemiologic data relating CRP to CVD. The intermediate CRP levels
were observed in AI men and EC men with similar waist circumferences. Using the recent ethnicity specific cut-off values for waist circumference, AI-DM2 patients had a more outspoken abdominal obesity compared to EC-DM2. As several reports in literature link central and overall adiposity to CRP levels in AIs, we expected higher CRP levels in AI-DM2. These relatively low levels of CRP were therefore compatible with the hypothesis of an attenuated inflammatory response in these patients. Further studies should be performed to explore the possible abrogation of inflammation in high-risk subjects without overt CVD.

The most interesting observation was the relatively low CIMT values in AIs, despite longer duration of diabetes and worse glycemic control. This could be a race-related phenomenon, which is in line with the observation of smaller luminal diameters in AIs. To date, IMT studies on predictive power have not taken diameter into account. In our subjects a significant variability of IMT for a given diameter was observed (data not shown), indicating the need for further explorative studies. There are no firm data on ethnicity-specific IMT values. We observed a median CIMT of 0.66 mm (± 0.12). Previous IMT studies in AIs have reported CIMT values of 0.59 mm (± 0.17) in non-diabetics and 0.63 mm (± 0.22) in DM2 patients living in South India; and CIMT values of 0.93 ± 0.36 mm versus 0.85 ± 0.21 mm in DM2 with and without retinopathy, respectively, have been reported in the same population. Based on our and other studies we calculated that future prospective comparative studies in different ethnic groups would require a sample size of at least 115 AIs versus 115 ECs to detect a 0.05 mm difference in CIMT with a power of 0.80 and a two-sided significance of 0.05.

The low CIMT observed may also have been due to pathophysiologic differences between AI-DM2 and EC-DM2 leading to slower progression of CIMT. Pathophysiologic changes directly related to diabetes seem unlikely as DM2 was milder in EC than in AI in this study. Thus, low CIMT is for instance not readily explained by decreased glycosylation of the extracellular matrix. Other candidate pathophysiologic mechanisms influencing CIMT progression in AI-DM2 could be endothelium-dependent, i.e. intrinsic or environmental acquired resistance against oxidative stress. In this regard the lower smoking rates in AI-DM2 may be of relevance. Mechanisms could also be endothelium-independent and more related to the pathophysiology of the intima. An attenuated intimal inflammatory response, in line with the intermediate levels of low-grade inflammation observed, would be such a mechanism.

In summary, the data presented provide a first description of vascular parameters in AI-DM2 from Surinam without CVD. In these patients, we observed ethnicity-defined, significantly lower CIMT than EC-DM2, despite presence of a number of robust cardiovascular risk factors. Following this interesting observation, reported for the first time, we propose that atheroprotective mechanisms are in play, slowing progression of CIMT and CVD. This and other similar AI cohorts should be intensively researched to unravel the protective factor(s).
REFERENCES


